Hologic (FRA:HO1) Research & Development: €217 Mil (TTM As of Dec. 2025)


FRA:HO1 Hologic Inc FRA:HO1
57 GF Score
Price €65.00
GF Value €70.17
! 4 Warning Signs
View Full Analysis

What is Hologic Research & Development?

Hologic FRA:HO1 57 Research & Development is €217 Mil as of Dec. 2025. GuruFocus rates FRA:HO1 with a GF Score™ of 57/100 and a GF Value™ of €70.17. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hologic's Research & Development for the three months ended in Dec. 2025 was €52 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €217 Mil.

Hologic  (FRA:HO1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hologic Research & Development Related Terms

Hologic Research & Development Historical Data

* Premium members only.

The historical data trend for Hologic's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic Research & Development Chart

Hologic Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 234.86 286.23 275.76 245.79 211.47

Hologic Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.59 56.89 53.23 55.47 51.67
FRA:HO1
57GF Score
Hologic Inc FRA:HO1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hologic Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €217 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €217 Mil mean?
Hologic (FRA:HO1) has a Research & Development of €217 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Hologic and its competitors.
Is Hologic's Research & Development too high?
Hologic's current Research & Development is €217 Mil. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Research & Development compare to WST and COO?
Hologic's Research & Development of €217 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hologic and its competitors. Hologic's current Research & Development is €217 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current Research & Development of €217 Mil. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current Research & Development is €217 Mil. Hologic's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hologic (FRA:HO1), the current Research & Development is €217 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hologic (FRA:HO1) Overvalued in 2026?

Based on GuruFocus' analysis, Hologic stock appears to be undervalued. The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.

Key valuation signals for FRA:HO1:

  • Research & Development: €217 Mil
  • GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hologic Business Description

Address 250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score

Get the complete analysis for FRA:HO1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€70.17
GF Value